Technology | Proton Therapy | August 18, 2016

ProteusONE is the first FDA cleared and CE marked compact solution using image guided IMPT

ProteusONE, IBA, FDA approval, FDA clearance of ProteusONE, compact proton therapy
ProteusONE, IBA, FDA approval, FDA clearance of ProteusONE, compact proton therapy

A room layout for the IBA ProteusOne compact proton therapy system.


August 18, 2016 — IBA (Ion Beam Applications SA) has received U.S. Food and Drug Administration (FDA) clearance for its new super conducting accelerator, which is the latest development, essential to the ProteusONE compact Intensity Modulated Proton Therapy (IMPT) solution, that required approval from regulatory authorities. 

The FDA clearance makes ProteusONE, the only compact proton therapy solution in the industry, that is certified to treat patients in the United States with optimized pencil beam scanning (PBS) and image guidance.
 
IBA has already signed 13 contracts to provide its compact proton therapy solution worldwide. The FDA clearance is an important milestone that will ensure on-time delivery of all of IBA’s current and future contracts.
 
“FDA clearance of our ProteusONE's new super conducting accelerator will be a significant market accelerator for proton therapy in the United States, because ProteusONE provides the most advanced treatment mode within the most compact and affordable system,” said Beth Klein, president of IBA Proton Therapy North America. “Any hospital considering proton therapy can now afford it through the ProteusONE’s lower capital and operating costs without making any clinical compromise. Ultimately, this will make proton therapy more accessible to the radiation therapy patients in the United States who can benefit from it.”
 
The ProteusONE is the world’s only FDA cleared and CE marked compact solution that uses image guided IMPT. With IBA’s industrialized production together with full CE approval and FDA clearance, IBA is now able to install complete proton therapy system in less than 12 months.
 
The ProteusONE is equipped with pencil beam scanning, a technology that offers high sub-millimeter precision treatment, which allows delivery of very high levels of conformity and dose uniformity, even in complex-shaped tumors, whilst at the same time sparing the surrounding healthy tissue.
 
For more information: www.iba-worldwide.com


Related Content

News | FDA

June 10, 2024 — Siemens Healthineers announces the Food and Drug Administration clearance of the Biograph Trinion, a ...

Time June 10, 2024
arrow
News | Breast Imaging

June 7, 2024 — Scholars and studies funded by Susan G. Komen(R), the world’s leading breast cancer organization ...

Time June 07, 2024
arrow
News | Radiopharmaceuticals and Tracers

June 7, 2024 — Shine Technologies, LLC, a pioneer in next-generation fusion-based technology, today announced a new ...

Time June 07, 2024
arrow
News | Information Technology

June 4, 2024 — International medical imaging IT and cybersecurity company Sectra has launched a new diagnostic IT module ...

Time June 04, 2024
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

As we flip the page to a new month on our calendars, here is a look at the Top 10 pieces of content viewers were reading ...

Time June 04, 2024
arrow
News | Radiation Oncology

June 3, 2024 — The American Society for Radiation Oncology (ASTRO) published an updated clinical guideline that details ...

Time June 03, 2024
arrow
News | Lung Imaging

May 31, 2024 — To further the fight against global lung cancer, Qure.ai, a leader in healthcare artificial intelligence ...

Time May 31, 2024
arrow
News | Oncology Information Management Systems (OIMS)

May 30, 2024 — RaySearch Laboratories AB announced the release of the latest version of RayCare, the next generation ...

Time May 30, 2024
arrow
News | Radiation Therapy

May 23, 2024 — RaySearch Laboratories AB and C-RAD announced a collaboration agreement, aiming at jointly developing ...

Time May 23, 2024
arrow
News | Artificial Intelligence

May 22, 2024 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, recently ...

Time May 22, 2024
arrow
Subscribe Now